^(18)F-FDG PET/CT预测肺腺癌EGFR基因突变状态的研究进展  

Research progress of ^(18)F-FDG PET/CT in predicting EGFR gene mutation status in lung adenocarcinoma

作　　者：夏鹏 唐立钧[1] 丁重阳[1] 李天女[1] XIA Peng;TANG Lijun;DING Chongyang;LI Tiannü(Department of Nuclear Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学第一附属医院核医学科,江苏南京210029

出　　处：《南京医科大学学报（自然科学版）》2022年第6期875-879,共5页Journal of Nanjing Medical University(Natural Sciences)

基　　金：江苏省卫生计生委科研项目(Z201502)。

摘　　要：近年来原发性肺癌的靶向药物研究飞速发展,其中针对表皮生长因子受体(epidermal growth factor receptor,EGFR)基因靶点的药物EGFR酪氨酸激酶抑制剂(EGFR-tyrosine kinase inhibitor,EGFR-TKI)对绝大多数EGFR突变型患者有很好的疗效。但EGFR-TKI对于野生型患者或者耐药性突变患者疗效甚微。因此行靶向治疗之前必须对EGFR突变状态进行检测。^(18)F-脱氧葡萄糖(^(18)F-fluorodeoxyglucose,^(18)F-FDG)正电子发射型计算机断层显像/计算机体层成像(positron emission computed tomography/computed tomography,PET/CT)则可以在患者没有条件行有创性基因检测时对EGFR的突变状态进行预测评估。本文就^(18)F-FDG PET/CT显像预测肺腺癌EGFR基因突变状态的研究进展进行综述。The research on targeted drugs for primary lung cancer has developed rapidly in recent years. Among them,epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKI),which aim on the EGFR gene target,can affect the vast majority of EGFR mutation patients and have good effect. However,EGFR-TKIs have little effect on patients with wild-type or drug-resistant mutations. Therefore,EGFR mutation status detected is needed before targeted therapy.^(18)F-fluorodeoxyglucose(^(18)F-FDG)positron emission tomography/computed tomography(PET/CT)can predict EGFR mutation status in patients who are not eligible for invasive genetic testing. This article reviewed the research progress of^(18)F-FDG PET/CT imaging in the prediction of EGFR gene mutation status in lung adenocarcinoma.

关 键 词：EGFR 肺腺癌 PET/CT 

分 类 号：R734.2[医药卫生—肿瘤]